Solstein Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Solstein Capital’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-112	Closed	-$13K	–	271
2019 Q4	$13K	Buy	+112	New	+$11.2K	0.03%	236

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Solstein Capital's ALNY Position: Q1 2020 in Review

Solstein Capital sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2020, closing a stake of 112 shares — an estimated $13K sold.

Solstein Capital first reported a position in ALNY in Q4 2019 and held it in 1 quarter. The position peaked at $13K in Q4 2019. 330 funds tracked by Wall St. Rank hold ALNY as of Q1 2020.

Solstein Capital reported no remaining Alnylam Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Solstein Capital sold 112 Alnylam Pharmaceuticals shares in Q1 2020, an estimated $13K.
Solstein Capital first reported a position in Alnylam Pharmaceuticals in Q4 2019 and held it in 1 quarter.
Solstein Capital's Alnylam Pharmaceuticals position peaked at $13K in Q4 2019.
330 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2020.

Based on Solstein Capital's 13F filing for Q1 2020, filed 12 May 2020.